A Phase I, Single-Centre, Randomised, Double-Blind, Placebo Controlled Single-Ascending Dose, Study to Assess the Safety, Tolerability, Pharmacokinetics of AZD8529 in Healthy Male Japanese Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs AZD 8529 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Acronyms JSAD
- Sponsors AstraZeneca
- 20 Aug 2009 Actual end date (July 2009) added as reported by ClinicalTrials.gov.
- 20 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 May 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.